Evidence map›Paper›PMID 38764224›Full record

ArticleACS nano2024

Plant-Derived Anti-Human Epidermal Growth Factor Receptor 2 Antibody Suppresses Trastuzumab-Resistant Breast Cancer with Enhanced Nanoscale Binding.

Chanyong Park, Kibum Kim, Yerin Kim, Rong Zhu, Lisa Hain, Hannah Seferovic, Min-Hyeok Kim, Hyun Joo Woo, Hyunju Hwang, Seung Ho Lee and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Article
  3. Biofilms: from the cradle of life to life support.NPJ biofilms and microbiomes · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chanyong ParkSchool of Mechanical Engineering, Sungkyunkwan University, Suwon 16419, Korea.
Kibum KimDepartment of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 06974, Korea.
Yerin KimDepartment of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 06974, Korea.
Rong ZhuDepartment of Applied Experimental Biophysics, Institute of Biophysics, Johannes Kepler University Linz, 4040 Linz, Austria.ORCID 0000-0001-7553-7249
Lisa HainDepartment of Applied Experimental Biophysics, Institute of Biophysics, Johannes Kepler University Linz, 4040 Linz, Austria.
Hannah SeferovicDepartment of Applied Experimental Biophysics, Institute of Biophysics, Johannes Kepler University Linz, 4040 Linz, Austria.
Min-Hyeok KimSchool of Mechanical Engineering, Sungkyunkwan University, Suwon 16419, Korea.
Hyun Joo WooMajor of Nano-Bioengineering, College of Life Sciences and Bioengineering, Incheon National University, Incheon 22012, Korea.
Hyunju HwangDepartment of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 06974, Korea.
Seung Ho LeeMajor of Nano-Bioengineering, College of Life Sciences and Bioengineering, Incheon National University, Incheon 22012, Korea.
Sangmin KimDepartment of Breast Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Jeong Eon LeeDivision of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Peter HinterdorferDepartment of Applied Experimental Biophysics, Institute of Biophysics, Johannes Kepler University Linz, 4040 Linz, Austria.ORCID 0000-0003-2583-1305
Kisung KoDepartment of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 06974, Korea.
Sungsu ParkSchool of Mechanical Engineering, Sungkyunkwan University, Suwon 16419, Korea.ORCID 0000-0003-3062-1302
Yoo Jin OhDepartment of Applied Experimental Biophysics, Institute of Biophysics, Johannes Kepler University Linz, 4040 Linz, Austria.ORCID 0000-0002-9636-3329

Funding

Austrian Science Fund FWF V 584
6 · The paper itself

Abstract

Traditional monoclonal antibodies such as Trastuzumab encounter limitations when treating Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer, particularly in cases that develop resistance. This study introduces plant-derived anti-HER2 variable fragments of camelid heavy chain domain (VHH) fragment crystallizable region (Fc) KEDL(K) antibody as a potent alternative for overcoming these limitations. A variety of biophysical techniques,

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesTrastuzumabAnimalsAntineoplastic Agents, ImmunologicalCell Line, TumorCell ProliferationFemaleHumansMiceAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumab

Identifiers

PMID38764224
PMCPMC11210341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.